Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea

Next Previous
X
Search
Trial Profile

ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Acronyms ESCORT-HU

    • Most Recent Events

    • 12 Dec 2023 Results (n=2923) evaluating the incidence of leg ulcers with prolonged HU treatment in ESCORT-HU and ESCORT-HU extension trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Oct 2021 Results published in the American Journal of Hematology
    • 06 Nov 2019 Results (n=1906) released at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top